You searched for "PSA"
Neuroendocrine bladder tumour
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...
Impact of case volume on outcomes of ureteroscopy for ureteral stones
With the ever-increasing focus on patient safety, centralisation of services for major procedures is becoming more common. Using data from the Clinical Research Office of the Endourological Society (CROES) Ureteroscopy Global Study database, a prospective observational multicentre study created to...Can dogs smell prostate cancer?
For centuries we have known that man’s best friend has an exceptional sense of smell. ‘Sniffer’ dogs are found in a wide range of roles, including drug and explosive detection as part of airport security, helping emergency services locate survivors...Shared decision-making – minimising the mismatch
In Western countries, we are spoilt for choice in almost every aspect of our lives, but does that reflect also in healthcare? While we have taken some big strides towards shared decision-making with our patients, the age-old physician dominance remains...Nurse practitioner TRUS biopsy: training and preparation
As prostate cancer rates increase, many urology departments rely on multi-professional teams to diagnose and manage patients with prostate cancer. The aim of this article is to highlight the skills, training and preparation required for nurse practitioners to undertake trans-rectal...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
Curing pure CIS with radical surgery: lessons learned
As carcinoma in situ (CIS) theoretically has no ability to invade or metastasise, performing radical cystectomy for CIS-only disease should be curative. In this single centre review over 37 years, 1964 patients undergoing cystectomy were analysed with 52 undergoing surgery...REPORT: Urology News Patient Engagement Evenings
Towards the end of 2019 the team at Urology News began making plans for our first event. An educational study day focusing on how to improve patient engagement in urology was to be held in Edinburgh at the end of...
RN or PN for small RCCs – the debate continues
This is a retrospective study to evaluate kidney function and overall survival (OS) in patients who underwent partial nephrectomy (PN) and radical nephrectomy (RN) for RCCs <4cm. They looked at 2110 patients who underwent RN/PN for T1a renal cell carcinomas...
Role of emergency ureteroscopy in the management of ureteric stones
Emergency ureteroscopy for all acute stone patients is not widespread in the UK but this is not the case elsewhere. In Auckland, New Zealand, it is commonly carried out in the emergency setting to reduce pressure on elective lists and...
Surgical and pathological outcome of partial nephrectomy: robotic versus laparoscopic approach
Nephron sparing surgery has become the standard surgical treatment for small renal masses (<4cm). Laparoscopic partial nephrectomy (LPN) is shown to be superior to the open approach (OPN) in peri and postoperative morbidity; however, it requires advanced skills and has...
